Video

Dr. Gandara on the Utility of TMB in NSCLC

David R. Gandara, MD, discusses the utility of tumor mutational burden in non–small cell lung cancer.

David R. Gandara, MD, director, Thoracic Oncology Program, professor, senior advisor to director, UC Davis Comprehensive Cancer Center, and a 2017 Giant of Cancer Care® in Lung Cancer, discusses the utility of tumor mutational burden (TMB) in non–small cell lung cancer (NSCLC).

​Along with PD-L1​, recent data suggest that TMB is another predictive biomarker for checkpoint inhibitors, says Gandara. However, TMB varies significantly between different cancer types and within individual patients, making TMB a complex biomarker.

​Recently, pembrolizumab (Keytruda) received its second biomarker-based indication from the FDA for adult and pediatric patients with unresectable or metastatic TMB-high solid tumors. According to Gandara, while this approval is a step forward in this space, it raises questions that need to be answered.

Notably, NSCLC is associated with a high mutational burden compared with other cancers as many patients were former smokers. As such, TMB may have many implications regarding the use of immunotherapy in NSCLC, Gandara concludes.

Related Videos
Paolo Caimi, MD
Jennifer Scalici, MD
Steven H. Lin, MD, PhD
Anna Weiss, MD, associate professor, Department of Surgery, Oncology, associate professor, Cancer Center, University of Rochester Medicine
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Hematology/Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Victor Moreno, MD, PhD
Haley M. Hill, PA-C, discusses the role of multidisciplinary management in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses preliminary data for zenocutuzumab in NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses how physician assistants aid in treatment planning for NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses DNA vs RNA sequencing for genetic testing in non–small cell lung cancer and pancreatic cancer.